Antiplatelet agents, including aspirin, aspirin/dipyridamole, and clopidogrel, are the recommended first-line therapies for secondary ischemic stroke prevention.
What are the recommended antiplatelet therapies for secondary stroke prevention?
Antiplatelet agents such as aspirin, aspirin/dipyridamole, and clopidogrel remain the mainstays of secondary ischemic stroke prevention.
Stroke is the third leading cause of death in the United States. Antiplatelet agents are the mainstays of ischaemic stroke prevention. The therapies recommended for initial therapy include aspirin (50 - 325 mg) daily, the combination of aspirin (25 mg) and extended-release dipyridamole (200 mg) b.i.d., or clopidogrel (75 mg) daily. Ticlopidine 250 mg b.i.d. is approved for stroke prevention but is no longer a first-line therapy. This article reviews the literature on antiplatelet agents for secondary stroke prevention.
Crawford et al. (Mon,) conducted a review in Secondary stroke prevention. Antiplatelet agents was evaluated. Antiplatelet agents, including aspirin, aspirin/dipyridamole, and clopidogrel, are the recommended first-line therapies for secondary ischemic stroke prevention.